Toppublicaties

Een selectie van wetenschappelijke toppublicaties.

Een chronologisch overzicht van toonaangevende publicaties uit CPCT-studies en partnerprojecten.

20264

DRUP·2026
BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol
Haj Mohammad SF, et al. European Journal of Cancer.
Naar publicatie →
DRUP·2026
Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the Drug Rediscovery Protocol
Spiekman IAC, et al. International Journal of Cancer.
Naar publicatie →
PRIME-ROSE·2026
Procedures of data merging in precision cancer medicine: the PRIME-ROSE project
van der Pol H, et al. Acta Oncologica.
Naar publicatie →
DRUP·2026
Prospective evaluation of genomics-guided off-label treatment
Verkerk K, et al. Nature.
Naar publicatie →

20253

DRUP·2025
Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol
Verkerk K, et al. Clinical Cancer Research.
Naar publicatie →
PRIME-ROSE·2025
Accelerating precision oncology by converging pragmatic trials and real-world evidence
Taskén K, Mahon P. Nature Reviews Drug Discovery.
Naar publicatie →
The Dark Genome (BEACON)·2025
Regulatory grammar in human promoters uncovered by MPRA-based deep learning
BEACON consortium Nature.
Naar publicatie →

20249

DRUP·2024
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer: Results from the Drug Rediscovery Protocol
Verkerk K, et al. Clinical Cancer Research.
Naar publicatie →
DRUP·2024
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Zeverijn LJ, et al. Clinical Cancer Research.
Naar publicatie →
DRUP·2024
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Geurts BS, et al. Clinical Cancer Research.
Naar publicatie →
PRIME-ROSE·2024
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
Taskén K, et al. Acta Oncologica.
Naar publicatie →
DRUP·2024
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol
Spiekman IAC, et al. The Oncologist.
Naar publicatie →
DRUP·2024
Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the Drug Rediscovery Protocol (DRUP)
Spiekman IAC, et al. European Journal of Cancer.
Naar publicatie →
Immunotherapy in lung cancer·2024
Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer
van de Haar J, et al. Clinical Cancer Research.
Naar publicatie →
DAP / cemiplimab·2024
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol
Verkerk K, et al. The Lancet Regional Health – Europe.
Naar publicatie →
Microbiome·2024
A pan-cancer analysis of the microbiome in metastatic cancer
Battaglia TW, et al. Cell.
Naar publicatie →

20233

DRUP·2023
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials
Zeverijn LJ, et al. International Journal of Cancer.
Naar publicatie →
A biomarker for chemotherapy·2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
van de Haar J, et al. Nature Medicine.
Naar publicatie →
Immunotherapy in colorectal cancer·2023
Gamma-delta T cells are effectors of immunotherapy in cancers with HLA class I defects
de Vries NL, et al. Nature.
Naar publicatie →

20221

DAP·2022
Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform
Zeverijn LJ, et al. The Lancet Oncology.
Naar publicatie →

20211

Actionable genome·2021
Limited evolution of the actionable metastatic cancer genome under therapeutic pressure
van de Haar J, et al. Nature Medicine.
Naar publicatie →

20192

Hartwig DB·2019
Pan-cancer whole-genome analyses of metastatic solid tumours
Priestley P, et al. Nature.
Naar publicatie →
DRUP·2019
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
van der Velden DL, et al. Nature.
Naar publicatie →

Een selectie van wetenschappelijke toppublicaties.

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the Drug Rediscovery Protocol

Procedures of data merging in precision cancer medicine: the PRIME-ROSE project

Prospective evaluation of genomics-guided off-label treatment

Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol

Accelerating precision oncology by converging pragmatic trials and real-world evidence

Regulatory grammar in human promoters uncovered by MPRA-based deep learning

Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer: Results from the Drug Rediscovery Protocol

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol

PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe

Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol

Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the Drug Rediscovery Protocol (DRUP)

Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

A pan-cancer analysis of the microbiome in metastatic cancer

Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

Gamma-delta T cells are effectors of immunotherapy in cancers with HLA class I defects

Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform

Limited evolution of the actionable metastatic cancer genome under therapeutic pressure

Pan-cancer whole-genome analyses of metastatic solid tumours

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs